Pivot Pharma (PVOT.C): can a new CEO turn a cannabis science co. into a profit machine?

Perusing Pivot Pharmaceuticals’ (PVOT.C) website you might think you’ve stumbled onto Pfizer’s (PFE.NYSE) “Proprietary IP” link. “RTIC infused substrates”? “Supercritical extraction”? “Phospholipid bilayers”? Anyone? In fact, if you strip away the tech-talk – Pivot’s business model is not that hard to wrap your head around. Pivot is a “science-based medical […]

Chemesis (CSI.C) receives $5.2 million purchase order from Happy Tea

In the cannabis “Get-Big-Fast” era, where weed companies buy stuff (grow-ops, dispensaries, websites, manufacturing plants, brands etc.) and post gigantic quarterly losses, it’s refreshing to see one company do it the old-fashioned way. On July 15, 2019 Chemesis International (CSI.C) announced a partnership with U.S.-based Happy Tea, a brand of […]

Hemptown buys FDA-approved plant with $6 mil/year existing revenue

I once consulted with a veteran CEO (potash, lithium, tech, gold) who told me, “Before I take a company public, I’ve got 60 press releases written in my head”. Since the man had created over $1 billion in enterprise value, I wasn’t going to argue with his roll-out template. His […]

LiveWell (LVWL.C) supplies CBD oil to Tilray (TLRY.NASDAQ) – but you’ll have to wait to buy shares

On March 14, 2019 LiveWell (LVWL.C) announced that it has finalized a CBD supply agreement with Tilray (TLRY.NASDAQ). LiveWell will supply Tilray with 150 kg of CBD oil per month. In August, 2019 that will ramp up to 300 kilograms of hemp-derived CBD isolate per month, or an equivalent amount […]